Bermekimab, an inhibitor of IL-1α, showed promising results in a Phase II open-label trial with hidradenitis suppurativa (HS) patients, demonstrating a significant reduction in inflammatory lesions even after anti-tumor necrosis factor (TNF) therapy failure without severe drug-related adverse events (51, 54, 55). Here, TNF is linked to hidradenitis suppurativa.